Abstract
This podcast episode reviews recent advances in the treatment of IDH1-mutant acute myeloid leukemia (AML), focusing on the mechanisms, efficacy, and safety profiles of approved IDH1 inhibitors. The purpose is to present expert insights and clinical data from key trials that underscore the clinical benefits of these targeted therapies. Through discussion of key findings from pivotal clinical trial studies, including data supporting the use of these agents in both newly diagnosed and relapsed or refractory (R/R) settings, the episode highlights significant outcomes such as increased overall response and prolonged duration of remission in patients treated with IDH1 inhibitors. The analysis examines critical factors including treatment sequencing, combination regimens, and toxicity management, particularly the monitoring and mitigation of differentiation syndrome and QT interval prolongation. Emphasis is placed on the clinical rationale for individualized therapy selection and the importance of repeat mutation testing at diagnosis and relapse to guide treatment decisions. The results obtained from these clinical trials provide evidence that integrating oral targeted agents into the management of relapsed or refractory AML improves patient outcomes, especially for older or unfit patients who cannot undergo intensive chemotherapy. In conclusion, the episode demonstrates that the evolving use of IDH1 inhibitors, supported by rigorous clinical evidence, represents a promising advance in AML treatment by offering more precise, effective, and tolerable therapeutic options.